HUE026000T2 - Immunogén peptid-hordozó konjugátumok és eljárások elõállításukra - Google Patents

Immunogén peptid-hordozó konjugátumok és eljárások elõállításukra Download PDF

Info

Publication number
HUE026000T2
HUE026000T2 HUE04814839A HUE04814839A HUE026000T2 HU E026000 T2 HUE026000 T2 HU E026000T2 HU E04814839 A HUE04814839 A HU E04814839A HU E04814839 A HUE04814839 A HU E04814839A HU E026000 T2 HUE026000 T2 HU E026000T2
Authority
HU
Hungary
Prior art keywords
peptide
carrier
protein
polypeptide
conjugate
Prior art date
Application number
HUE04814839A
Other languages
English (en)
Inventor
Rasappa G Arumugham
A Krishna Prasad
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34700142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE026000(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HUE026000T2 publication Critical patent/HUE026000T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645Dendrimers; Multiple antigen peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (7)

  1. Szabadalmi IgéBypbaibk
    1, Eljárás peptidirotnunogén konjugáláséin egy vágy több hmlmíóa esopoftot tattataasrn proíeio/polipepilö hordozóhoz a peptidimmunogén egy ambtosimfeak reaktív csoportján keresztül, amely eljárás magában foglalja a következő lépéseket: (k> a protein'polipepísd hordozó egy vagy több funkciós csefPripmk derivátízáláse, ezáltal reaktiv helyeket tartalmazó derivatizáít hordozó előállítása, ahol a hordozó a kővetkezőkből álló csoportból mn kiválasztva: CRM;??, Sireptococem pyogenes ORF1224, Streptococcus pyogeMs Ö8P i 664, Streptococcus pyogmmÍM¥2452 és Ckkmvémpmmmmiae ORF T8S8; (b| az (a) lépőében előállhótt, derivatizáít proteio/polipeptkl hordozó reagáltatása a pephdimmonogén egy ummósavának reaktív csópótRávai olyan reakciókörühnények között, aboi a peptidimrouROgéa a ftipketós <^psMnt'.kemsMin derivririzált és (ci a komugátum további magákstása bf-aeeiiicisriearnmßal, ezáltal a derivatizáít proteirvjpilpeptid bmdozőn szabad, reaktiv, reakcióba nem lépett funkciós csoportok inaktiválása, editál: a hordozó miklklöképességének megőrzése oly módon, hogy megtartja &amp; peptidimmanogén ellen a kívánt immunválasz kiváltásának képességét, amely képesség hordozó nélkül mm jeletme meg, ahol a feörfugátum képlete a következő:
    ahol € jelentése a proteín/polipeptid hordozó» Xd jelentése a protein/polipeptié hordozó derivatizáít tónké tós eisoporíja, F jelentése peptidimmunogén, R jeSémése sapkázó moiuknla, n értéke nullánál nagyobb, de 8S-néi kisebb egész szám vagy &amp;S» és p ériéke mdlánáí nagy obb, de áS-oél kisebb egész szám vagy 85,
  2. 2, Féptidímmunogén^proleintbolpepiM hordozó koajogátum, amelynek képlete a következő: ahol
    C jeiéidése a köveíkezökfeö! álló csoportból kiválasztott proteui/polipeptkl hordozó: CRM^?, $fä§ßM' .0RF 1224, Str^tMocctiS pyogene* ORF 1664» Streptccmcks pyogenes OSF24S2 és pnekmmêe 1858, Xd jelentése a ptőieirkpolipeptld hordozó egy aminösávának derivatizáít funkciós Csoportja P jelentése a proteirdpolipeptid bmídoző ammosavánáh derivatizáít ftíukctós csopórijáboz kovalensen kapcsolt p«f tidirhmunogéu molekula, E jelentése a konjugátum M-aeetilelszteamlnuaí való reakciója által képzett sapkázó molekula, amely kovalensen a protein/polspeptid hordozó aminosavának derivatizáít funkciós csoportjához van kapcsolva, ezáltal megőrzi a hordozó omködőkégességéi oly triódon, hogy megtartja a . pepidáruaiunogén ellen a kívánt iímnoaválasa kiváhásáaak képességét, amely képesség hordozó nélkül nem jelenne meg, » értéke nullánál nagyobb, de SS-nél kisebb egész szám vagy 85, és p értéke nullánál nagyobb, de §S-né! kisebb egész szám vagy 85,
  3. 3. Âz 1. igénypont szerinti eljárás vagy ai igénypont szerinti pptiídlmomriOgén-iMdeií^olípeptíd hordozó kopagáthon ahol a protein/pohpepiid hordozó CEM»?.
  4. 4. Az 1. igénypont szerinti eljárás vagy a 2. igénypont szerinti peptidiínnítmogéR-proteín/polipepttd hordozó konjugátom, ahol a peptídimmnnogén a következőkből álló csoportból van kiválasztva: bakteriális fehérje, vtrnsteMíjé, gamMfelPije, parazhníehérje és eukarióta fehérje.
  5. 5. Az i. igénypont szerinti eljárás, amely magában foglalja eisztein bérlését a peptidirornomrgPs C~ vagy N-ieraünálfeán. Ő. Az 5, igénypont szerinti e|árás, ahol a eisztein a pepídlmmonogén C-termináiísára vas beépítve.
  6. 7. Az 5. igényponí szerinti eljárás, ahol a eisztein a peptidfntnnarQgén N-terathmhsára van beépítve. 8, A 2, igénypont szerinti pepidlmoionogén-poíenvpoíítmpbd hordozó kopngáhn», ahol a peptid-hnnmnogén tartalmaz a pepödimmtmogén amPoteítnmáHsáo vagy a peptidimmanogéo karhoxiíermmálisán lévő eiszteint. E A 8. igénypont szerinti peptidinnnunogoti-proteio^oiipeptid hordozó tajagátnm, ahol a eisztein a pepííditomuntpénkarböxiterntiöáiisán található, H) A 8. igénypont szerinti pepíiábnmunogén-proíein/polipeptid hordozó konjugátom, ahol a eisztein 3 peptídmmmnogéó änWnöterininäiiÄ
  7. 11, Az I, igénypom szerinti eljárás vagy a 2. igénypont szerinti pepidimmmtogempotetpjmiipepid trente# konjngátntn, ahol a protein/poíipeptíÖ hordozó égy; vágy több amioösav-molektrlájának: funkciós esop>riÍakér«szlkötö reagens alkalmazásával derivadzálva van. !2. A Íl.igénypont szerinti eljárás vagy pepidimnrnnogbn-proieippolipepid hordozó konjugátum, ahol a protelrdpoiipeptP hordozó haloaeetilálő hatóanyaggal van reagálhatva, S3. Inmmrsogéo készítmény, amely 2-4. vagy 8-12. igénypontok bármelyike szerínE pegildtmmuáögén pröíeinípoiipepíí«! hordozóval képzett könjagátumát tartaknazza egy vagy több gyógyászatilag elfogadható segédanyaggal, higítószerrel étvágy adjuvánssal egyött. 14. A 13. igénypont szerinti immunogén készítmény, ahol az egy vagy több adjnváos a Mlvelkezökból álló csoportból vas kiválásivá: GMA3SF, 522 SE, 1L-12, aMnfoiutn-ibszMt, alnmmânmdsProsiil, Mycabmiemm tuhermlosisBordetella ymrttíssm bakteriális llpopoitszaebaridok, amlnoslkii-glskozamio-foszfát vegydietek, MPE1** f3~t>deacllálí monoEszfcriiriipid A), polipeptid, Quil A, QS-21, perhísszíszlexirs fPFj, E cdl höfebílis tóPn (ET), IB I o,IBI f, iL-2, ÏL-4, ÍL-S, :IL-ó, fl.,-7, 11,-g, 11,-iö, ÎB-13, 1L-14, 1L~15,1,-16,ÏB47, 11,-18, snîerièron- a, interistón-p, interleron-y, G-€lSF, THF- a p TNF-ß,
HUE04814839A 2003-12-17 2004-12-17 Immunogén peptid-hordozó konjugátumok és eljárások elõállításukra HUE026000T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53048003P 2003-12-17 2003-12-17

Publications (1)

Publication Number Publication Date
HUE026000T2 true HUE026000T2 (hu) 2016-04-28

Family

ID=34700142

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE04814839A HUE026000T2 (hu) 2003-12-17 2004-12-17 Immunogén peptid-hordozó konjugátumok és eljárások elõállításukra

Country Status (28)

Country Link
US (1) US20070134762A1 (hu)
EP (1) EP1701968B1 (hu)
JP (1) JP4764830B2 (hu)
KR (1) KR101157694B1 (hu)
CN (1) CN1984676A (hu)
AR (1) AR046960A1 (hu)
AU (1) AU2004299501B2 (hu)
BR (1) BRPI0417744B8 (hu)
CA (1) CA2549132C (hu)
CR (1) CR8444A (hu)
DK (1) DK1701968T3 (hu)
EA (2) EA012984B1 (hu)
EC (1) ECSP066655A (hu)
ES (1) ES2546175T3 (hu)
HK (1) HK1091219A1 (hu)
HU (1) HUE026000T2 (hu)
IL (1) IL176006A0 (hu)
MY (1) MY146566A (hu)
NO (1) NO340432B1 (hu)
NZ (1) NZ548352A (hu)
PL (1) PL1701968T3 (hu)
PT (1) PT1701968E (hu)
SG (2) SG149013A1 (hu)
SI (1) SI1701968T1 (hu)
TW (1) TWI355390B (hu)
UA (1) UA93854C2 (hu)
WO (1) WO2005058940A2 (hu)
ZA (1) ZA200604957B (hu)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20060188512A1 (en) * 2003-02-01 2006-08-24 Ted Yednock Active immunization to generate antibodies to solble a-beta
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MY144231A (en) 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
CA2582194A1 (en) * 2004-10-05 2006-04-20 Neuralab Limited Methods and compositions for improving recombinant protein production
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
CN101171031B (zh) * 2005-05-05 2011-09-28 默沙东公司 防止和治疗阿尔茨海默病的肽偶联物组合物和方法
RU2415865C2 (ru) * 2005-06-17 2011-04-10 Вайет СПОСОБЫ ОЧИСТКИ БЕЛКОВ, СОДЕРЖАЩИХ ОБЛАСТЬ Fc
ZA200803759B (en) 2005-11-02 2009-10-28 Univ Duke Concurrent chemotherapy and immunotherapy
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
CA2638841A1 (en) * 2006-02-24 2007-08-30 Chiesi Farmaceutici S.P.A. Anti-amyloid immunogenic compositions, methods and uses
WO2007112079A2 (en) * 2006-03-24 2007-10-04 Duke University Multivalent immunogen
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EA200970166A1 (ru) * 2006-08-01 2009-06-30 Дзе Скриппс Рисерч Инститьют Вакцины и способы для регуляции ожирения
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2231180B1 (en) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
EP2145898A1 (en) 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
CN101671689B (zh) * 2009-07-29 2013-05-01 中国农业科学院上海兽医研究所 含日本血吸虫基因的重组表达载体及其应用
IN2012DN00446A (hu) * 2009-07-30 2015-05-15 Pfizer Vaccines Llc
AU2010320031B2 (en) * 2009-11-16 2015-07-16 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. (Poly)-glycerolphosphate-based anti-gram positive bacterial vaccine
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011133227A2 (en) 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphyloccocus vaccine
WO2011137181A1 (en) 2010-04-27 2011-11-03 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for moraxella vaccine
WO2011149778A1 (en) 2010-05-26 2011-12-01 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for neisseria meningitis vaccine
JP2013538558A (ja) 2010-07-19 2013-10-17 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Tlr媒介疾患を治療するためのtoll様受容体(tlr)の膜貫通型ドメインに基づくペプチド
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
ES2628596T3 (es) 2010-11-29 2017-08-03 Akershus Universitetssykehus Procedimientos y composiciones para monitorizar la actividad fagocítica
CN102526724B (zh) * 2011-01-14 2015-07-22 四川大学 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途
EP2709656B1 (en) 2011-05-18 2019-03-27 Matrivax, Inc. Protein matrix vaccine compositions including polycations
KR101281098B1 (ko) * 2011-06-30 2013-07-02 주식회사 녹십자 B형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도
EP2766384B1 (en) * 2011-10-10 2016-11-23 Yeda Research and Development Co. Ltd. Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
CN102731659B (zh) * 2012-06-07 2014-05-07 北京交通大学 一种6×His-C99重组蛋白及其制备方法和应用
JP6148729B2 (ja) 2012-07-04 2017-06-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 共有結合している抗原−抗体結合体
CN103497927B (zh) * 2013-10-21 2016-02-10 深圳大学 表达分泌金葡菌肠毒素蛋白的重组bcg活菌菌株、活菌疫苗及其构建方法和应用
WO2015101587A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
CN111228509A (zh) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN106470707A (zh) * 2014-05-07 2017-03-01 应用分子运输有限责任公司 用于口服递送生物活性货物的cholix毒素衍生的融合分子
CN104059142B (zh) * 2014-07-03 2016-11-23 江南大学 一种用于制备沙门氏菌交叉型抗体的免疫原的合成方法
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
JP6867289B2 (ja) * 2014-12-18 2021-04-28 ビオメリューBiomerieux 合成ビエピトープ化合物
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位,含此表位的多抗原肽及应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN107648618B (zh) * 2017-09-27 2020-05-08 国家纳米科学中心 一种药物递送体系及其制备方法与应用
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN110018253A (zh) * 2019-04-15 2019-07-16 艾美卫信生物药业(浙江)有限公司 一种生物制品中游离蛋白含量的高效液相测定方法
CN111499724A (zh) * 2020-04-15 2020-08-07 上海领潮生物新材料有限公司 一种s-腺苷同型半胱氨酸-鸡卵白蛋白偶联物的制备方法
CN111896737B (zh) * 2020-08-03 2023-07-07 北京望尔生物技术有限公司 一种蛇形菌素人工抗原在酶联免疫试剂盒中的应用
US11571481B2 (en) 2020-12-21 2023-02-07 Cornell University Peptide-linked drug delivery system
EP4346893A2 (en) * 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024025397A1 (ko) * 2022-07-29 2024-02-01 주식회사 엘지화학 항원 전달용 재조합 융합 단백질 및 이의 이용

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5245015A (en) * 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5089603A (en) * 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5192540A (en) 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
AU8081491A (en) 1990-06-01 1991-12-31 Cetus Corporation Compositions and methods for identifying biologically active molecules
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
ES2097925T3 (es) 1991-09-18 1997-04-16 Affymax Tech Nv Metodo para sintetizar diversas colecciones de oligomeros.
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ,ミヒャエル 油除去装置を備えたエンジン
DE69333107T2 (de) * 1992-02-11 2004-01-29 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
AU686579B2 (en) 1992-10-01 1998-02-12 Cold Spring Harbor Laboratory Complex combinatorial chemical libraries encoded with tags
DE69434079T2 (de) 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
WO1995012608A1 (en) 1993-11-02 1995-05-11 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL115933A0 (en) 1995-11-09 1996-01-31 Oramir Semiconductor Ltd Process and apparatus for oblique beam revolution for the effective laser stripping of sidewalls
PT859959E (pt) 1995-11-10 2003-12-31 Elan Corp Plc Peptidos que aumentam o transporte atraves dos tecidos e metodos para a sua identificacao e utilizacao
AU729579B2 (en) 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
US6962984B2 (en) * 1996-12-05 2005-11-08 Nihon University IgA nephropathy-related DNA
DE69612205T2 (de) 1996-12-16 2001-08-30 Nederlanden Staat Verfahren zur Kupplung von Polysacchariden und Proteinen
US5877220A (en) * 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EP1078093B1 (en) 1998-02-27 2011-06-08 The Trustees of The University of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
US6645503B1 (en) * 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
CA2264970A1 (en) * 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
DE69937571T2 (de) 1998-09-30 2008-09-04 The Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutiertes cholera holotoxin als hilfsmittel
CA2363118A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
US6945135B1 (en) * 1999-09-09 2005-09-20 L. H. Thomson Company, Inc. Bicycle stem for enlarged handlebar portions and associated methods
US20030190322A1 (en) * 2000-03-31 2003-10-09 Peter Kaastrup Immunostimulating properties of a fragment of tgf-beta
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
DE60234695D1 (de) 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
US20030135035A1 (en) * 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
AU2002357007A1 (en) * 2001-11-21 2003-06-10 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
MY144231A (en) * 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME

Also Published As

Publication number Publication date
BRPI0417744A8 (pt) 2017-08-08
PL1701968T3 (pl) 2015-11-30
TW200533681A (en) 2005-10-16
WO2005058940A3 (en) 2006-10-26
CA2549132A1 (en) 2005-06-30
EA012984B1 (ru) 2010-02-26
CR8444A (es) 2008-02-20
ECSP066655A (es) 2006-12-20
AU2004299501A1 (en) 2005-06-30
JP2008505052A (ja) 2008-02-21
ZA200604957B (en) 2008-01-08
BRPI0417744B1 (pt) 2020-11-03
EP1701968B1 (en) 2015-06-03
BRPI0417744B8 (pt) 2021-05-25
NZ548352A (en) 2009-09-25
MY146566A (en) 2012-08-30
US20070134762A1 (en) 2007-06-14
EA010060B1 (ru) 2008-06-30
UA93854C2 (ru) 2011-03-25
BRPI0417744A (pt) 2007-04-10
EA200800300A1 (ru) 2008-10-30
EP1701968A4 (en) 2007-10-03
PT1701968E (pt) 2015-09-11
CA2549132C (en) 2017-03-07
NO20062687L (no) 2006-09-15
AR046960A1 (es) 2006-01-04
TWI355390B (en) 2012-01-01
WO2005058940A2 (en) 2005-06-30
KR20070027502A (ko) 2007-03-09
AU2004299501B2 (en) 2010-12-23
SG182163A1 (en) 2012-07-30
DK1701968T3 (da) 2015-06-22
EP1701968A2 (en) 2006-09-20
EA200601169A1 (ru) 2007-04-27
NO340432B1 (no) 2017-04-24
IL176006A0 (en) 2006-10-05
HK1091219A1 (en) 2007-01-12
KR101157694B1 (ko) 2012-06-20
CN1984676A (zh) 2007-06-20
JP4764830B2 (ja) 2011-09-07
ES2546175T3 (es) 2015-09-21
SG149013A1 (en) 2009-01-29
SI1701968T1 (sl) 2015-08-31

Similar Documents

Publication Publication Date Title
EP1701968B1 (en) Immunogenic peptide carrier conjugates and methods of producing same
EP2336147B1 (en) A beta immunogenic peptide carrier conjugates and methods of producing same
ARUMUGHAM et al. Patent 2549132 Summary
MXPA06006822A (en) Immunogenic peptide carrier conjugates and methods of producing same